CClinicalTrials.gg
Active, not recruitingNCT06746428ACTIVATEUpdated Sep 1, 2026

Activity Coaching During Pelvic Radiation Therapy

An interventional study of Exercise Coaching in Radiation Therapy, Gynecologic Cancer and Exercise Therapy, sponsored by Inova Health Care Services. Active, not recruiting at 4 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Inova Health Care Services · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Research has shown that for women who are undergoing pelvic radiation therapy, fatigue is a common side effect. Fatigue that occurs during radiation therapy can make it harder to perform daily living activities. While there are studies that recommend exercise as a treatment for fatigue in cancer patients and survivors, there are currently no studies that focus on the role of exercise for women undergoing pelvic radiation therapy. The purpose of this study is to see if incorporating an activity coaching program is helpful in improving treatment-related fatigue for women undergoing pelvic radiation therapy for endometrial cancer.

Read the detailed description

The exercise coaching program is a program in which Participants will have ten weekly check-ins with a certified exercise coach. During check-ins, Participants and the exercise coach will set weekly goals. Participants will try to incorporate activities that are easy and enjoyable for them. These visits can be scheduled at their convenience and choose whether these check-ins will be in-person, or virtually.

All Participants who agree to join this study will be asked to:

  • Participate in a program with an exercise coach to set weekly goals for activity. The timing of when the program will start will be based on the group Participants are assigned to.
  • Receive a Fitbit to track how active they are, their heart rate and how many steps they've have taken.
  • Complete 4 surveys which will be given throughout the course of the study.
  • Complete a short 6-minute walking test to see how their heart and lungs respond to exercise. This test will be completed 4 times throughout the study.
  • Participate in an interview with the principal investigator at the end of the study for feedback on how the study can be improved.

The study team expects to enroll 16 patients in this study. Participants will either be placed in the Immediate Start Activity Coaching Program or the Delayed Start Activity Coaching Program. 8 patients will be assigned to the Immediate Start Group, and 8 will be assigned to the Delayed Start Group. Participants will spend about 6 months in this study.

02

Conditions studied

  • Radiation Therapy
  • Gynecologic Cancer
  • Exercise Therapy
03

In context

Lead sponsor

Inova Health Care Services is the lead sponsor of 84 studies on the registry; 20 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 8 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • At least 18 years of age
  • Pathologic diagnosis of endometrial cancer (any histology, Stage I-IVA)
  • Has undergone modified radical or radical hysterectomy
  • Plan to receive adjuvant treatment with pelvic external beam radiation therapy at ISCI
  • ECOG performance status of 0-1
  • Patient has a computer, smart phone, or tablet virtual access to the web-based platform and email
  • Able to read, understand and provide written informed consent
  • Deemed appropriate for unmonitored exercise by treating physician based on the following evidence-based criteria (1)

    • Walk without any assistance or assistance device
    • Absence of significant cognitive impairment
    • Absence of high risk for falls
  • Participant does not need to refrain from any activity

Exclusion criteria

Exclusion Criteria:

  • Unable to schedule and attend coaching visits
  • Participation in a regular exercise program of ≥150 minutes of moderate intensity exercise a week at baseline
  • Unable to perform the five-times stand test
  • Medical comorbidities including:

    • Unstable angina
    • Uncontrolled dysrhythmias
    • Acute pulmonary embolus
    • Active pulmonary infection
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Immediate Start Group

    Participants in this group will start the intervention during the first week of radiation therapy and continue through and post-completion of radiation

    Behavioral: Exercise Coaching

  • Experimental
    Delayed Start Group

    Participants in this group will start 6-8 weeks post - radiation and continue 16-19 weeks post-radiation.

    Behavioral: Exercise Coaching

Interventions

  • BehavioralExercise Coaching

    An exercise coaching program tailored for women with Stage I-IVA endometrial cancer who have undergone total or modified radical hysterectomy with surgical staging. The intervention targets a total of 8 participants who are planned to complete pelvic external beam radiation therapy as part of their adjuvant treatment.

06

What researchers measure

Primary outcomes

  1. Feasibility of a Randomized Trial: Participant Adherence to Exercise Coaching Sessions

    Participant adherence to coaching sessions will be defined as complete adherence when engaging in 10 of the 10 planned exercise coaching sessions and high adherence as engaging in at least 7 of the planned 10 exercise coach check-ins. Participant adherence will be considered feasible if 70% of participants adhere to the coaching sessions.

    Time frame: Enrollment to end of follow up, up to 24 months

Secondary outcomes

  1. Change in patient-reported fatigue

    Measurement of changes in the level of fatigue as reported by patients, using a Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue. FACIT-F fatigue subscale consists of 13 items. Patients rate the intensity of their fatigue symptoms on a scale of 0 to 4 (0=not at all and 4=very much). Total FACIT-F fatigue subscale score ranges from 0 to 52 with higher scores less fatigue and lower scores more fatigue

    Time frame: Enrollment to end of follow up, up to 24 months

  2. Change in patient-reported bowel/urinary toxicity

    Assessment of changes in the severity of bowel and urinary toxicity symptoms, as reported by patients, using Expanded Prostate Cancer Index Composite (EPIC) bowel and urinary short form assessments. The EPIC-15 is a short-form version that includes 15 items across two domains: Urinary Function and Bowel Habits. Each item in the EPIC-15 is scored on a Likert scale, and the scores are transformed to a 0-100 scale, with higher scores indicating better quality of life.

    Time frame: Enrollment to end of follow up, up to 24 months

  3. Change in patient-reported Quality of Life (QOL)

    Measurement of changes in the quality of life based on patient-reported outcomes, using Patient-Reported Outcomes Measurement Information System (PROMIS-29) Profile v2.1. It includes 29 items that assess seven key areas: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles/Activities and Pain Interference. Each question usually has five response options ranging in value from one to five. The scores are then converted to T-scores using a scoring table. Higher T-Scores for Physical Function indicate better physical functioning, Higher T-Scores for Anxiety and Depression indicate more severe symptoms. Higher T-Scores for Fatigue and Sleep Disturbance indicate more fatigue or sleep problems. Higher T-Scores in ability to participate in social roles/activities indicate better ability to participate in social roles and activities. Higher T-Scores for Pain Interference means more interference from pain in daily activities and intense pain

    Time frame: Enrollment to end of follow up, up to 24 months

  4. Change in patient-reported cognitive function

    Evaluation of cognitive function changes reported by patients, measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function Short Form 4a. This form contains 4 items. Each item is scored on a Likert scale from 1 (Never) to 5 (Very often). Raw scores are converted to T-scores using a scoring table. Higher T-scores indicate better cognitive function.

    Time frame: Enrollment to end of follow up, up to 24 months

  5. Change in patient-reported sexual function and satisfaction

    Changes in sexual function and satisfaction, as reported by patients, using a Patient-Reported Outcomes Measurement Information System (PROMIS) Brief Profile Sexual Function and Satisfaction. Each item is scored on a Likert scale, and then converted into a T-Score. Higher T-scores indicate better sexual function and satisfaction.

    Time frame: Enrollment to end of follow up, up to 24 months

  6. Change in patient-reported self-efficacy

    Measurement of changes in patients' perceived self-efficacy, using Patient-Reported Outcomes Measurement Information System (PROMIS) Self-Efficacy for Chronic Conditions. Each item is scored on a Likert scale, and then converted into a T-Score. Higher T-scores indicate greater self-efficacy.

    Time frame: Enrollment to end of follow up, up to 24 months

  7. Change in distance walked during the 6-Minute Walk Test (6MWT)

    Measurement of the change in distance walked by patients during the 6-Minute Walk Test, a standardized test used to assess physical function.

    Time frame: Enrollment to end of follow up, up to 24 months

07

Study locations

4 sites
  • Inova Schar Cancer Institute - Alexandria
    Alexandria, Virginia 22311, United States
  • Inova Schar Cancer Institute
    Fairfax, Virginia 22031, United States
  • Inova Schar Cancer Institute - Fair Oaks
    Fairfax, Virginia 22033, United States
  • Inova Schar Cancer Institute - Loudoun
    Leesburg, Virginia 20176, United States
08

References and documents

Study documents

  • Study protocol · May 12, 2025
  • Informed consent form · May 12, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06746428
Lead sponsor
Inova Health Care Services
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Jan 27, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Avani Rao, MD
principal investigator · Inova Health Care Services

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion